Your new post is loading...
The RV144 ‘Thai trial’ of an HIV vaccine candidate resulted in an unprecedented 31% protection rate among participants – a
result that sparked something of a revival in the HIV vaccine field. Despite this encouraging result, the protection rate was still considered to be too low for the vaccine to be useful. Since then, many HIV vaccines have come and gone – with the NIAID’s HVTN 505 trial being the latest casualty in the drive to stem the HIV pandemic. However, researchers at the Duke Human Vaccine Institute have published researched inProceedings of the National Academy of Sciences (May 6th 2013) which pinpoints a previously unknown interaction between IgA and IgG antibodies as the cause of a lack of response to the RV144 vaccine.
Killer T-cell graphic by Russell Kightely Media
VERY interesting, if true: IgA - supposedly the Ab of choice for mucosal surface protection - interfering with IgG, and stopping killer T / NK cells from binding and killing infected cells?